Decreased Adiponectin Levels and Effect of Atorvastatin Treatment in Hyperlipidemic Patients

Abstract

Objectives: Atherosclerotic diseases such as coronary heart disease, myocardial infarction and stroke are leading causes of morbidity and mortality. Hyperlipidemia is among the major risk factors for atherosclerotic diseases. Atorvastatin, a member of statins wich is a potent lipid lowering drugs is used widely in hyperlipidemia. Serum levels of adiponectin that is produced in adipose tissue and that regressed atherosclerosis were shown to fall down in the presence of such atherosclerosis risk factors as hypertension, diabetes and hyperlipidemia. In the present study we aimed to examine serum adiponectin levels in hyperlipidemia and at the end of atorvastatin treatment. Material and Methods: The study enrolled 26 non-diabetic hyperlipidemic patients and 10 healthy individuals matching hyperlipidemia group in terms of age, sex, body mass index and blood pressure. The 26 hyperlipidemic patients were treated with 20 mg/day atorvastatin for 8 weeks. Serum lipid and adiponectin levels were examined at the beginning of the treatment and after 8 weeks. Results: Adiponectin levels were found 18.8±6.8 µg/mL in healthy individuals and 3.7±1.3 µg/mL in hyperlipidemic patients, the difference between them being statistically significant (p

Keywords

• -

Hiperlipidemik Olgularda Azalmış Serum Adiponektin Düzeyi ve Atorvastatin Tedavisinin Etkisi

Öz

Giriş: Koroner arter hastalığı, miyokard infarktüsü, inme gibi ateroskleroz temelli hastalıklar morbidite ve mortalitenin önde gelen sebeplerindendir. Hiperlipidemi aterosklerotik hastalıkların majör risk faktörlerindendir ve hızlanmış ateroskleroz ile sonuçlanmaktadır. Potent lipid düşürücülerden statinlerin bir üyesi olan atorvastatin hiperlipidemide yaygın olarak kullanılmaktadır. Yağ dokudan üretilen, aterosklerozu gerileten adiponektinin; obezite, hipertansiyon, diyabet, hiperlipidemi gibi ateroskleroz risk faktörlerinin varlığında serum düzeylerinin azaldığı ortaya konulmuştur. Bu çalışmada hiperlipidemide ve atorvastatin tedavisi sonunda serum adiponektin düzeylerini incelemeyi amaçladık. Gereç ve Yöntem: Çalışmaya non-diyabetik hiperlipidemik 26 olgu ile yaş, cinsiyet, vücut kitle indeksi ve kan basınçları hiperlipidemi grubuna uygun 10 sağlıklı olgu alındı. Hiperlipidemik 26 olgu 20 mg/gün atorvastatin ile 8 hafta süre tedavi edildi. Tedavinin başlangıcında ve 8 hafta sonra serum lipit ve adiponektin düzeylerine bakıldı. Bulgular: Sağlıklı olgularda adiponektin düzeyi 18.8±6.8 µg/mL iken hiperlipidemi grubunda 3.7±1.3 µg/mL tespit edildi ve aralarındaki fark istatistiksel olarak anlamlı idi (p

Anahtar Kelimeler

• Ateroskleroz, hiperlipidemi, atorvastatin ve adiponektin

Kaynakça

1. Ford ES, Giles WH, Mokdad AH. The distribution of 10-Year risk for coronary heart disease among US adults: findings from the National Health and Nutrition Examination Survey III. J Am Coll Cardiol 2004; 43: 1791-1796.
2. Rosenson RS. Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities. Atherosclerosis 2004; 173: 1-12.
3. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 2001; 37: 1053- 1539.
4. Groop L, Orho-Melander M. The dysmetabolic syndrome. Intern Med. 2001; 250: 105-120.
5. Tokgözoğulu L, Özer N. Ateroskleroz patogenezi. Özcan N. Koroner kalp hastalıkları. 1. Baskı. Ankara 1997. 129-163.
6. Gordon DJ, Probstfeld JL, Garrison RJ. High-density lipoprotein cholesterol and cardiovascular disase: four prospective American study. Circulation 1989; 37: 47-53.
7. Kwak BR, Mulhaupt F, Mach F. Atherosclerosis: anti- inflammatory and immunomodulatory activities of statins. Autoimmun Rev 2003; 2: 332-338.
8. Blumenthal RS. Statins: effective antiatherosclerotic therapy. Am Heart J 2000; 139: 577–583.

9. Rajala MW, Scherer PE. Minireview: The adipocyte--at the crossroads of energy homeostasis, inflammation, and atherosclerosis Endocrinology 2003; 144: 3765-3773.
10. Yang WS, Lee WJ, Funahashi T, et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 200; 86: 3815- 3819.
11. Matsubara M, Maruoka S, Katayose S. Decreased plasma adiponectin concentrations in women with dyslipidemia. J Clin Endocrinol Metab 2002; 87: 2764-2769.
12. Diez JJ, Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol 2003; 148:293-300.
13. Chandran M, Phillips SA, Ciaraldi T, Henry RR. Adiponectin: more than just another fat cell hormone? Diabetes Care 2003; 26: 2442-2450.
14. Miyazaki T, Shimada K, Mokuno H, Daida H. Adipocyte derived plasma protein, adiponectin, is associated with smoking status in patients with coronary artery disease. Heart 2003; 89: 663.
15. Adamczak M, Wiecek A, Funahashi T, Chudek J, Kokot F, Matsuzawa Y. Decreased plasma adiponectin concentration in patients with essential hypertension. Am J Hypertens 2003; 16: 72-75.
16. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin in obesity. Biochem Biophys Res Commun. 1999; 257: 79-83.
17. Karşıdağ K. Klinik pratikte periferik insülin resistansı ölçüm yöntemleri. Folia 2002; 2: 12-15.
18. Ouchi N, Kihara S, Arita Y. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999; 100: 2473-2476.
19. Yokota T, Oritani K, Takahashi I, et al. Adiponectin, a new member of the family of soluble defence collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood. 2000; 96: 1723-1732.
20. Kubota N, Terauchi Y, Yamauchi T, Kubota T, Moroi M & Matsui J. Disruption of adiponectin causes insulin resistance and neointimal formation. Journal of Biological Chemistry. 2002; 277: 25863–25866.
21. Berg AH, Combs TP, Scherer PE. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab 2002;13:84-89.
22. Ouchi N, Kihara S, Arita Y, Nishida M, Matsuyama A, Okamoto Y. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001; 103: 1057–1063.
23. Okamoto Y, Arita Y, Nishida M, et al. An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular walls. Horm Metab Res 2000; 32: 47-50.
24. Egan BM, Greene EL, Goodfriend TL. Insulin resistance and cardiovascular disease. Am J Hypertens 2001; 14: 116-125.
25. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nature Medicine 2001; 7: 941–946.
26. Stefan N, Vozarova B, Funahashi T, Matsuzawa Y, Weyer C, Lindsay RS. Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes 2002; 51: 1884–1888.
27. Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R. Adiponectin gene expression is inhibited by beta-adrenergic stimulation via protein kinase A in 3T3-L1 adipocytes FEBS Lett 2001; 507:142-146.
28. Shand BI, Scott RS, Elder PA, George PM. Plasma adiponectin in overweight, nondiabetic individuals with or without insulin resistance. Diabetes Obes Metab 2003; 5:349-353.
29. Lindsay RS, Funahashi T, Hanson RL, et al. Adiponectin and development of type 2 diabetes in the Pima Indian population Lancet. 2002; 360: 57-58.
30. Lihn AS, Ostergard T, Nyholm B, Pedersen SB, Richelsen B, Schmitz O. Adiponectin expression in adipose tissue is reduced in first-degree relatives of type 2 diabetic patients. Am J Physiol Endocrinol Metab 2003; 284: 443-448.
31. Fogari R, Derosa G, Lazzari P, et al. Effect of amlodipine- atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic patients with insulin resistance. Am J Hypertens 2004; 17: 823-827.
32. Sonmez A, Baykal Y, Kilic M, et al. Fluvastatin improves insulin resistance in nondiabetic dyslipidemic patients. Endocrine. 2003 Nov; 22: 151-154.
33. Paolisso G, Barbagallo M, Petrella G, et al. Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients. Atherosclerosis 2000; 150: 121–127.
34. Melenovsky V, Malik J, Wichterle D, et al. Comparison of the effects of atorvastatin or fenofibrate on nonlipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemia. Am Heart J 2002; 144:E6.
35. Shetty GK, Economides PA, Horton ES, Mantzoros CS, Veves A. Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care 2004; 27: 2450-2457.
36. Fuhrman B, Koren L, Volkona N, Keidar S. Atorvastatin therapy in hypercholesterolemic patients supresses cellular uptake of oxidized-LDL by Differentiating monocytes. Atherosclerosis 2002; 164: 179-185.
37. Kabul Tarihi: 09.03.2007